This study is in progress, not accepting new patients
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
Summary
- Eligibility
- for people ages 18-60 (full criteria)
- Location
- at UC Irvine UCSD
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Chiesi Farmaceutici S.p.A.
- ID
- NCT03566017
- Phase
- Phase 3 Fabry Disease Research Study
- Study Type
- Interventional
- Participants
- About 97 people participating
- Last Updated